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PORRECTIONS
ancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC, for the ADHERE Scientific Advisory Committee and
nvestigators. Clinical Presentation, Management, and In-Hospital Outcomes of Patients Admitted With Acute Decompensated
eart Failure With Preserved Systolic Function: A Report From the Acute Decompensated Heart Failure National Registry
ADHERE) Database. J Am Coll Cardiol 2006;47:76–84.
he “Weight loss, 10 lbs” row of Table 6 of this article was printed incorrectly. The correct table is printed below. We apologize for
his error.
doi:10.1016/j.jacc.2006.02.027
In the article, “ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic
Heart Failure in the Adult—Summary Article: A Report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the
2001 Guidelines for the Evaluation and Management of Heart Failure),” by Hunt et al, which
appeared in the September 20, 2005, issue of the journal (J Am Coll Cardiol 2005;46:1116–43),
the following clarifications should be made:
1. In Figure 1, under therapy for Stage B, the following text should be added below the listings
for Drugs: “DEVICES IN SELECTED PATIENTS: Implantable defibrillators.” See revised
figure below.
2. In Table 2, the legend defining HF is incorrect. The words “and asymptomatic left ventricular
dysfunction” should be deleted, leaving, “HF, heart failure.”
3. In Table 3, a dagger should be added after “Potassium-sparing diuretics.” In the legend, the
following definition should be added: “†Eplerenone, although also a diuretic, is primarily used
in chronic heart failure as a suppressor of the renin-angiotensin-aldosterone system.”
4. On page 1127, the following Class I recommendation should be added after recommendation
6: “7. Maximal exercise testing with or without measurement of respiratory gas exchange is
recommended to facilitate the prescription of an appropriate exercise program for patients
presenting with HF. (Level of Evidence: C)”
5. On pages 1127 and 1128, current recommendations 7, 8, 9, 10, 11, and 12 should be
renumbered 8, 9, 10, 11, 12, and 13 to accommodate the new recommendation 7.
6. On page 1128, in current recommendation 11, 6th line, “0.12 ms” should be changed to “120
ms” to read, “Patients with LVEF less than or equal to 35%, sinus rhythm, and NYHA
functional class III or ambulatory class IV symptoms despite recommended, optimal medical
therapy and who have cardiac dyssynchrony, which is currently defined as a QRS duration
greater than 120 ms, should receive cardiac resynchronization therapy unless contraindicated.
(Level of Evidence: A)”
7. On page 1128, in current recommendation 12, first line, the word “reasonable” should be
replaced with the word “recommended” to read, “Addition of an aldosterone antagonist is
able 6. Clinical Outcomes During Hospitalization.
Outcome
Systolic Function
No LVEF Assessment
(n  45,607)
Preserved
(n  26,322)
Reduced
(n  25,865) p*
ortality (%) 2.8 3.9 0.0001 4.8
ength of hospitalization (days, median [interquartile range]) 4.9 [3.1–7.6] 5.0 [3.2–8.1] 0.0001 3.8 [2.3–6.1]
dmitted to ICU (%) 18.9 24.7 0.0001 15.3
ength of ICU/CCU stay (days, median [interquartile range]) 2.7 [1.4–4.9] 3.0 [1.6–5.1] 0.0001 2.0 [1.0–3.8]
eight loss 79.8 80.7 0.0298 75.8
10 lbs (%) 26.9 30.4 0.0001 23.2
symptomatic at discharge (%) 55 55 0.21 51
Comparison between preserved and reduced systolic function groups.
CCU  coronary care unit; ICU  intensive care unit; LVEF  left ventricular ejection fraction.
ublished by Elsevier Inc.recommended in selected patients with moderately severe to severe symptoms of HF and
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April 4, 2006:1502–5reduced LVEF who can be carefully monitored for preserved renal function and normal
potassium concentration. Creatinine should be less than or equal to 2.5 mg/dL in men or less
than or equal to 2.0 mg/dL in women and potassium should be less than 5.0 mEq/l. (Under
circumstances where monitoring for hyperkalemia or renal dysfunction is not anticipated to be
feasible, the risks may outweigh the benefits of aldosterone antagonists.) (Level of Evidence: B)”
8. On page 1128, CLASS IIA recommendation 3, the level of evidence should be changed from A to
B to read, “The addition of a combination of hydralazine and a nitrate is reasonable for patients with
reduced LVEF who are already taking an ACEI and beta-blocker for symptomatic HF and who
have persistent symptoms. (Level of Evidence: B)”
9. On page 1129, right column, second paragraph, third line, the word “small” should be deleted.
doi:10.1016/j.jacc.2006.02.029
In the article, “ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic
Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Writing Committee to Update the 2001
Guidelines for the Evaluation and Management of Heart Failure),” by Hunt et al., which appeared
in the September 20, 2005, issue of the journal (J Am Coll Cardiol 2005;46:e1–82), the following
clarifications are needed:
1. In Figure 1, under therapy for Stage B, the following text should be added below the listings for Drugs:
igure 1. Stages in the development of heart failure/recommended therapy by stage. FHx CM indicates family history of cardiomyopa-
hy; ACEI, angiotensin converting enzyme inhibitor; and ARB, angiotensin receptor blocker.“DEVICES IN SELECTED PATIENTS: Implantable defibrillators.” See revised figure below.
